FREDERICK, Md., Aug. 3, 2009 (GLOBE NEWSWIRE) -- BioElectronics Corporation (Pink Sheets:BIEL), a maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced Alquemie Partners, a strategic research and advisory boutique, has issued a new research report on the Company. The analyst, Carrie Snyder, places a target price on the shares of between $0.30 and $0.50, should expected FDA clearances be granted.
"We are very excited about BioElectronics's drug-free pain relief and healing technologies and products. With the recent FDA panel recommendation to restrict certain dosages of Tylenol(r) and acetaminophen, we believe the timing of the Company's clinical study completions and FDA filings is optimal," commented Ms. Snyder. "BioElectronics is clearly addressing a significantly sized market with its patented drug-free technologies. Should FDA clearances be given, as we expect, we believe the price of these shares could rise significantly."
A copy of the report can be downloaded at the following location: http://www.bioelectronicscorp.com/Documents/ind_analyst.pdf
About Alquemie Partners
Alquemie Partners is a strategic advisory, research and business consultancy firm where Analyst Carrie Snyder is a co-founder and partner. Prior to founding Alquemie Partners in 2008, Ms. Snyder spent over ten years in the investment banking industry at leading firms such as JPMorgan Chase, Salomon Smith Barney and Wells Fargo Securities with many years in equity research at other Wall Street firms. More information on Alquemie Partners can be viewed at www.alquemiepartners.com.
About BioElectronics Corporation
BioElectronics Corporation is the maker of ActiPatch(r) Therapy, RecoveryRx(tm) Devices, HealFast(tm) Therapy (www.healfasttherapy.com) and the Allay(tm) family of inexpensive, disposable drug-free anti-inflammatory devices. For more information please see http://www.BioElectronicsCorp.com.
Tylenol is a registered trademark of McNeil Pharmaceutical, Inc.